Search

Physiotherapists (PTs) are at a significant risk of having musculoskeletal problems as a result of their jobs such as Work Related Musculoskeletal Disorders (WRMDs). WRMDs are described as injuries that involve a wide spectrum of inflammatory or degenerative diseases and disorders that result in pain or functional impairment, according to the World Health Organization. The aim of current study was to determine the prevalence of lumbosacral radiculopathy among pediatric physiotherapists in the ministry of health in Cairo, Egypt. Material and methods: two hundred participants included in this study from both sex with age ranged from 25-40 years. participants were assigned to Single group related measurement design. Specific questionnaire based on Roland Morris questionnaire (for back pain) and Modified Roland Morris questionnaire (for leg pain) (RMQ, RMQ-L) respectively. Results: there is a statically significant association between Age, BMI, working years, work hours per day and number of patients/day and lumbosacral radiculopathy; while sex had no significant association with lumbosacral radiculopathy. Subjects with age 30-37 years were 4.01 times more likely to have lumbosacral radiculopathy compared with subjects with age 25-29 years. Subjects working > 4h/day were 4.57 times more likely to have lumbosacral radiculopathy compared with subjects working 2-4 h/day. The results of this study showed that the point prevalence of lumbosacral radiculopathy was 30.5% (p > 0.05). Conclusion: according to this results, lumbosacral radiculopathy is common among Egyptian pediatric physiotherapists, Making Cairo's pediatric physiotherapists at a high-risk group, which necessitate appropriate intervention to manage such problem.

Objectives: To compare the impact of core stability exercises versus Biodex balance training on postural stability and sway among patients suffering from mechanical low back pain. Methods: The study was conducted in the outpatient clinic of the Faculty of Physical Therapy, Modern University for Technology and Information, between March and June 2023. This randomized, double?blind, pre?post measurement study included forty-eight patients have been participated in this study and divided into three groups, Group A (control group) (n = 18) were given stretching as well as strengthening exercises. Group B (n = 18) were given core stability exercises plus stretching as well as strengthening exercises. Group C (n = 18) were given Biodex balance training (limit of stability, maze, and random control modes training) plus stretching as well as strengthening exercises. The Biodex Balance System were utilized to quantify dynamic balance indices at baseline and six weeks following therapy. Statistical analysis among groups for eye open firm, eye closed firm, eye open foam, and eye closed foam revealed from the Modified clinical test of sensory interaction and balance which were the main outcome indicator. Results: The Within-Group analysis revealed substantial differences regarding postural stability as well as control of postural sway for groups B and C, both prior to and following the treatment program (p value < 0.05). The between-group analysis revealed statistically substantial variations across all variables following the therapy, with Group C exhibiting further pronounced differences compared to Groups A and B (p < 0.05). Conclusion: Enhancement in all measures of dynamic balance was shown following core stability training activities and Biodex balance training, with a greater degree of improvement seen after Biodex balance training.

Purpose: In preclinical models, radioimmunotherapy with (131)I-A5B7 anti-carcinoembryonic antigen (CEA) antibody ((131)I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone. We conducted a phase I trial determining the dose-limiting toxicity (DLT), maximum tolerated dose, efficacy, and mechanism of this combination in patients with gastrointestinal adenocarcinomas. EXPERIMENTAL DESIGN: Patients had CEA of 10 to 1,000 microg/L, QTc < or =450 ms, no cardiac arrhythmia/ischaemia, and adequate hematology/biochemistry. Tumor was suitable for blood flow analysis by dynamic contrast enhanced-magnetic resonance imaging (MRI). The starting dose was 1,800 MBq/m(2) of (131)I-A5B7 on day 1 and 45 mg/m(2) CA4P given 48 and 72 hours post-(131)I-A5B7, then weekly for up to seven weeks. Results: Twelve patients were treated, with mean age of 63 years (range, 32-77). Two of six patients at the first dose level had DLTs (grade 4 neutropenia). The dose was reduced to 1,600 MBq/m(2), and CA4P escalated to 54 mg/m(2). Again, two of six patients had DLTs (neutropenia). Of ten assessable patients, three had stable disease and seven had progressive disease. Single-photon emission computed tomography confirmed tumor antibody uptake in all 10 patients. DCE-MRI confirmed falls in kinetic parameters (K(trans)/IAUGC(60)) in 9 of 12 patients. The change of both pharmacokinetic parameters reached a level expected to produce efficacy in one patient who had a minor response on computed tomography and a reduced serum tumor marker level. Conclusions: This is believed to be the first trial reporting the combination of radioimmunotherapy and vascular disruptive agent; each component was shown to function, and myelosuppression was dose-limiting. Optimal dose and timing of CA4P, and moderate improvements in the performance of radioimmunotherapy seem necessary for efficacy.